Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Core Insights - Akari Therapeutics is set to present at the 2026 Biocom Global Partnering & Investor Conference, highlighting its focus on oncology biotechnology and antibody drug conjugates (ADCs) with novel immuno-oncology payloads [1][2]. Company Overview - Akari Therapeutics specializes in developing next-generation ADCs, particularly focusing on a unique payload, PH1, which targets RNA splicing [3]. - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [3]. - PH1 is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing potential to induce cancer cell death while activating both innate and adaptive immune responses [3]. - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, with potential synergy when combined with checkpoint inhibitors [3]. - The company has initiated IND enabling studies for AKTX-101, aiming to start its First-In-Human trial by late 2026 or early 2027 [3]. - Akari is also developing AKTX-102, targeting CEACAM5, a tumor antigen expressed in various solid tumors, leveraging the PH1 payload for enhanced tumor cell killing and immune activation [3].